EXTON, Pa., Oct. 29 /PRNewswire-FirstCall/ — ViroPharma
Incorporated (Nasdaq:
VPHM) today announced that William Roberts, vice president,
corporate communications of ViroPharma, will present at the
Oppenheimer 21st Annual Healthcare Conference at 3:55 P.M. ET on
Tuesday, November 2, 2010. The conference is being held at
the Waldorf=Astoria in New York City.
Charles Rowland, vice president and chief financial officer, of
ViroPharma, will present at the Lazard Capital Markets 7th Annual
Healthcare Conference at 1:45 P.M. ET on Wednesday, November 17,
2010. The conference is being held at the St. Regis Hotel in
New York City.
Mr. Rowland will also present at the 4th Annual Maxim Group
Growth Conference at 9:30 A.M. ET on Thursday, November 18, 2010.
The conference is being held at the Grand Hyatt in New York
City.
ViroPharma’s presentations will be webcast live for investors
through www.viropharma.com and
available for a period of 14 days following the conferences.
About ViroPharma Incorporated
ViroPharma Incorporated is an international biopharmaceutical
company committed to developing and commercializing innovative
products for physician specialists to enable the support of
patients with serious diseases for which there is an unmet medical
need, and providing rewarding careers to employees.
ViroPharma commercializes Cinryze™ (C1 esterase
inhibitor [human]) for routine prophylaxis against angioedema
attacks in adolescent and adult patients with hereditary angioedema
(HAE). ViroPharma commercializes Vancocin®, approved for
oral administration for treatment of antibiotic-associated
pseudomembranous colitis caused by Clostridium difficile and
enterocolitis caused by Staphylococcus aureus, including
methicillin-resistant strains (for prescribing
‘/>”/>
